Nanobiotix Data from Two Phase 1 NBTXR3 Studies at ELC
Nanobiotix announced two poster presentations at the 2025 European Lung Cancer Conference showcasing Phase 1 study data for JNJ-1900...
Jon Napitupulu
CEPI Funds Dyadic’s C1 for Protein Vaccine Development
Dyadic International received a $4.5 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore using their...
Briacell’s Phase 3 Breast Cancer Study Gets Positive Recommendation
BriaCell Therapeutics Corp. announced positive safety results from the second review of its Phase 3 study of Bria-IMT™ combined...
Medera Gets DSMB Clearance to Advance Phase 2 Portion of Phase 1b/2 Trial for Gene Therapy in Heart Failure
Medera Inc., a clinical-stage biopharmaceutical company, announced positive results from the Phase 1b portion of its MUSIC-HFrEF trial, evaluating...
Soquelitinib Data in T-Cell Lymphoma: Promising Results Unveiled
Corvus Pharmaceuticals released additional data from its Phase 1/1b clinical trial of soquelitinib, an oral ITK inhibitor, for T-cell...
Pathos AI Doses First Patient in Pocenbrodib Trial
Pathos AI has initiated a Phase 1b/2a clinical trial for its CBP/p300 inhibitor, pocenbrodib, in patients with metastatic castration-resistant...
Milestone Pharmaceuticals to Present Etripamil Data at ACC
Milestone Pharmaceuticals announced a poster presentation at the American College of Cardiology annual meeting (ACC25) from March 29th-31st, 2025,...
Celz-201-DDT FDA Clearance for Chronic Lower Back Pain Trial
Creative Medical Technology Holdings (CELZ) announced positive interim data from its Phase 1/2 trial of StemSpine using AlloStem (CELZ-201-DDT),...
WuGen Announces Dosing in Wu-CART-007 Trial
Wugen, Inc. has begun its pivotal Phase 2 trial of WU-CART-007, an off-the-shelf CAR-T cell therapy for relapsed or...
Genenta Secures €20M, Brain Tumor Trial Shows Promising Survival
Genenta Science secured €20 million (approximately $21.9 million) in financing from ENEA Tech and Biomedical (ETB) to support the...